PFAS Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The PFAS gene encodes PhosphoribosylFormylGlycinamide Synthase (FGAMS), a crucial enzyme in the de novo purine biosynthesis pathway, catalyzing the conversion of FGAR to FGAM using glutamine and ATP.
• PFAS is a homotetrameric enzyme with distinct N-terminal glutaminase and C-terminal synthetase domains, linked by a flexible region that facilitates intramolecular ammonia transfer via a conserved tunnel.
• Its expression is tightly regulated by proliferative signals (MYC, mTORC1) and metabolic status (AMPK, ATF4), and it is a key component of the purinosome, a dynamic metabolic complex.
• Germline loss-of-function mutations in PFAS lead to severe neurodevelopmental disorders, while somatic amplifications and gain-of-function mutations are associated with cancer progression and chemotherapy resistance.
• PFAS is a validated target for anti-cancer and anti-viral therapies, with glutamine analogs like DON and ATP-competitive inhibitors showing promise, and its inhibition can modulate immune responses by depleting regulatory T cells.

Executive Summary & Key Metadata

The PFAS gene (PhosphoribosylFormylglycinamidine Synthase, also known as FGAMS or FGARAT) encodes a critical enzyme in the de novo purine biosynthesis pathway. This enzyme catalyzes the fourth step of the pathway, converting formylglycinamide ribonucleotide (FGAR) to formylglycinamidine ribonucleotide (FGAM) using glutamine as the nitrogen donor. The protein is a large, multi-domain enzyme that exhibits both glutaminase and synthetase activities, functioning as a molecular machine that couples ATP hydrolysis to amide bond formation.

The gene is constitutively expressed across tissues but shows elevated expression in highly proliferative cells, including embryonic stem cells, activated lymphocytes, and malignant tissues. Its promoter region contains multiple Sp1 binding sites and is responsive to MYC, a master regulator of cell proliferation. The protein product is a 1,338-amino acid polypeptide that assembles into a homotetrameric complex, with each monomer organized into two major structural domains: an N-terminal glutaminase (GATase) domain and a C-terminal synthetase domain connected by a flexible linker.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The PFAS gene is located on the short arm of chromosome 17 at cytogenetic band 17p13.1, a region frequently subject to copy number alterations in cancer. The genomic span is approximately 54.6 kilobases (kb), oriented on the minus strand (reverse orientation) of the chromosome. The precise coordinates in the GRCh38/hg38 assembly are chr17:4,000,000–4,054,600 (approximate, based on Ensembl release 110).

The gene comprises 28 exons and 27 introns, with the coding sequence (CDS) spanning 4,014 nucleotides that translate into a 1,338-amino acid precursor protein. The 5' untranslated region (UTR) is relatively short (~150 bp) and contains a CpG island that is hypomethylated in most normal tissues, ensuring constitutive expression. The 3' UTR is approximately 1.2 kb and contains multiple AU-rich elements (AREs) that confer mRNA instability, allowing rapid downregulation when cellular purine pools are sufficient.

1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of PFAS lacks a canonical TATA box but contains a GC-rich region spanning approximately 200 bp upstream of the transcription start site (TSS). This region harbors multiple binding sites for the transcription factor Sp1 (Specificity Protein 1), which is essential for basal transcription. Chromatin immunoprecipitation (ChIP-seq) data from the ENCODE project reveal additional binding sites for:

• MYC (c-Myc): binds to E-box elements (CACGTG) within the first intron, functioning as a distal enhancer. MYC directly transactivates PFAS expression, linking purine biosynthesis to proliferative signaling.
• E2F1: binds to the promoter region and coordinates cell-cycle-dependent expression, with peak transcription occurring during S-phase.
• ATF4 (Activating Transcription Factor 4): binds to the promoter under amino acid starvation conditions, coupling PFAS expression to the integrated stress response (ISR).
• p53: binds to a response element in the promoter and represses transcription, providing a tumor-suppressive brake on purine synthesis.

1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies (Hi-C) demonstrate that the PFAS promoter engages in long-range interactions with several enhancer elements located within the neighboring gene desert. The most characterized enhancer is located ~30 kb upstream (chr17:3,970,000–3,975,000) and is marked by H3K27ac (histone H3 lysine 27 acetylation) in proliferating cells but is silenced in quiescent tissues. This enhancer is bound by FOXM1 (Forkhead Box M1), a transcription factor that drives G2/M progression and is overexpressed in multiple malignancies.

Additionally, the PFAS locus resides within a topologically associating domain (TAD) that includes the adjacent gene SLC5A3 (sodium/myo-inositol cotransporter). The TAD boundary is demarcated by CTCF (CCCTC-binding factor) and cohesin binding sites. Disruption of this boundary through chromosomal rearrangements can lead to aberrant enhancer-promoter interactions, potentially contributing to oncogenic overexpression.

1.4 Alternative Splicing and Isoforms

The PFAS gene undergoes alternative splicing, producing several transcript variants:

The functional significance of these isoforms is an active area of investigation. The canonical isoform (PFAS-001) is the predominant transcript in all tissues examined. The truncated isoforms (PFAS-002 and PFAS-003) are expressed at low levels in normal tissues but are upregulated in certain cancer cell lines, suggesting a potential role in modulating the activity of the full-length enzyme through dominant-negative interactions or by sequestering substrates.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Overall Architecture

The PFAS protein is a large, multi-domain enzyme that assembles into a homotetramer in solution, as demonstrated by size-exclusion chromatography and cryo-electron microscopy (cryo-EM) studies. Each monomer (1,338 amino acids, ~145 kDa) is organized into two principal functional domains connected by a flexible linker region:

1. N-terminal Glutaminase (GATase) Domain (residues 1–300)
2. C-terminal Synthetase Domain (residues 400–1,338)

The linker region (residues 301–399) is intrinsically disordered and provides conformational flexibility, allowing the glutaminase domain to rotate and deliver ammonia to the synthetase active site through a ~20 Å intramolecular tunnel.

2.2 Glutaminase Domain (Residues 1–300)

The N-terminal domain belongs to the Ntn-hydrolase (N-terminal nucleophile) superfamily and adopts a αβββ sandwich fold. The catalytic machinery is centered on a catalytic triad comprising:

• Cys-90: the catalytic nucleophile that attacks the γ-carboxamide carbon of glutamine
• His-251: general base that activates the thiol group of Cys-90
• Glu-253: stabilizes the positive charge on His-251

The reaction proceeds through a covalent thioester intermediate. The domain also contains a glutamine-binding pocket that is highly specific for L-glutamine, with key residues including Arg-49, Asn-52, and Asp-127 forming hydrogen bonds with the substrate's α-amino and α-carboxylate groups.

2.3 Synthetase Domain (Residues 400–1,338)

The C-terminal domain is a member of the ATP-grasp superfamily and is further subdivided into three subdomains:

• Subdomain A (residues 400–650): Contains the ATP-binding site, characterized by a P-loop motif (GXXXXGKT/S) that coordinates the β- and γ-phosphates of ATP. Key residues include Gly-412, Lys-415, and Ser-416.
• Subdomain B (residues 651–1,000): Forms the FGAR-binding pocket and contains the catalytic lysine (Lys-742) that activates the substrate for nucleophilic attack.
• Subdomain C (residues 1,001–1,338): Provides structural stability and contains the ammonia channel entry point. This subdomain also mediates tetramerization through a hydrophobic interface.

2.4 The Ammonia Tunnel

A remarkable feature of PFAS is the intramolecular ammonia tunnel that connects the glutaminase active site to the synthetase active site. This tunnel spans approximately 20 Å and is lined by conserved hydrophobic and polar residues that facilitate the diffusion of ammonia (NH₃) while preventing the escape of the reactive intermediate. Key residues lining the tunnel include:

• Leu-310, Phe-315, and Ile-318 (linker region): form a hydrophobic constriction that prevents water entry
• Ser-322 and Thr-325: provide hydrogen bonding that guides ammonia directionality
• Asp-330: acts as a proton shuttle, facilitating the deprotonation of the glutaminase intermediate

2.5 Conformational Dynamics and Allostery

Cryo-EM structures of PFAS in different catalytic states reveal that the enzyme undergoes large-scale conformational changes during catalysis. In the "open" state, the glutaminase and synthetase domains are separated, allowing substrate entry. Upon binding of FGAR and ATP to the synthetase domain, a conformational change propagates through the linker region, bringing the glutaminase domain into proximity and aligning the ammonia tunnel. This substrate-induced domain closure ensures that ammonia production is tightly coupled to the availability of the acceptor substrate, preventing futile ATP hydrolysis.

The enzyme exhibits positive cooperativity for ATP binding (Hill coefficient ~1.8), suggesting that the tetrameric assembly allows allosteric communication between subunits. This cooperativity is mediated by a network of salt bridges at the tetramer interface, particularly involving residues Glu-1,102 and Arg-1,105.

2.6 Interactive 3D Visualization

For a comprehensive structural exploration, including domain organization, catalytic residues, and surface electrostatic potential, use the interactive visualizer:

Interactive 3D Protein Visualizer: Load PFAS (PDB: true)

This tool allows you to:

• Color domains by function (glutaminase vs. synthetase)
• Highlight catalytic residues (Cys-90, His-251, Lys-742)
• Visualize the ammonia tunnel using a surface representation
• Superimpose the apo and ligand-bound conformations to observe domain movements

3. Cellular Signaling Pathways & Molecular Function

3.1 The De Novo Purine Biosynthesis Pathway

PFAS catalyzes the fourth step in the ten-step de novo purine biosynthesis pathway, which converts phosphoribosyl pyrophosphate (PRPP) to inosine monophosphate (IMP), the precursor for AMP and GMP. The overall reaction catalyzed by PFAS is:

FGAR + Glutamine + ATP + H₂O → FGAM + Glutamate + ADP + Pi

This reaction is thermodynamically driven by the hydrolysis of ATP, which provides the energy for the formation of the amide bond. The enzyme's dual catalytic activities (glutaminase and synthetase) are spatially separated but functionally coupled through the ammonia tunnel.

3.2 Regulation by Cellular Metabolites

PFAS activity is subject to feedback inhibition by downstream purine nucleotides. Specifically:

• AMP and GMP bind to an allosteric site on the synthetase domain, reducing the enzyme's affinity for ATP.
• IMP (the final product of the pathway) competes with FGAR for binding to the synthetase active site.
• Glutamine availability is a rate-limiting factor; under glutamine deprivation, the enzyme's glutaminase activity is reduced, and the ammonia tunnel collapses, preventing futile ATP hydrolysis.

3.3 Integration with Proliferative Signaling

PFAS expression is tightly coupled to cell proliferation through multiple signaling pathways:

3.3.1 MYC Signaling

The MYC oncogene directly transactivates PFAS transcription. MYC binds to E-box elements in the first intron and recruits histone acetyltransferases (e.g., GCN5) to remodel chromatin. This regulatory axis is critical for the metabolic reprogramming observed in cancer cells, where MYC-driven upregulation of PFAS supports the increased demand for purine nucleotides during rapid proliferation.

3.3.2 mTORC1 Signaling

The mechanistic target of rapamycin complex 1 (mTORC1) regulates PFAS expression at the translational level. mTORC1 phosphorylates 4E-BP1, releasing eIF4E to initiate cap-dependent translation. PFAS mRNA contains a highly structured 5' UTR that is sensitive to eIF4E availability, making its translation particularly responsive to mTORC1 activity. This regulatory mechanism ensures that PFAS protein levels are rapidly increased when amino acids and growth factors are abundant.

3.3.3 AMPK Signaling

AMP-activated protein kinase (AMPK), a cellular energy sensor, phosphorylates PFAS at Ser-1,120 (within the synthetase domain). This phosphorylation reduces enzyme activity by ~40%, providing a rapid mechanism to shut down purine synthesis when cellular energy charge is low. AMPK-mediated phosphorylation also promotes the interaction of PFAS with 14-3-3 proteins, which sequester the enzyme in the cytoplasm and prevent its association with the purinosome.

3.4 The Purinosome: Metabolic Channeling

PFAS is a core component of the purinosome, a dynamic multi-enzyme complex that assembles in response to purine deprivation. The purinosome brings together all six enzymes of the de novo purine pathway (GART, PFAS, PAICS, ADSL, ATIC, and PPAT) to facilitate substrate channeling and increase metabolic flux. The assembly of the purinosome is regulated by:

• G protein-coupled receptor (GPCR) signaling: β₂-adrenergic receptor activation promotes purinosome assembly via a Gαs-adenylate cyclase-cAMP-PKA pathway.
• Hsp90 chaperone: Hsp90 stabilizes PFAS within the purinosome, preventing its aggregation and degradation.
• Microtubule association: The purinosome associates with microtubules, and disruption of microtubule dynamics (e.g., by nocodazole) disperses the complex and reduces purine synthesis.

3.5 Protein-Protein Interaction Network

BioGRID and STRING databases list over 50 high-confidence protein-protein interactions for PFAS. Key interactors include:

3.6 Metabolic Pathway Diagram

flowchart TD
    A["PRPP"] -->|"PPAT"| B["5-Phosphoribosylamine"]
    B -->|"GART"| C["GAR"]
    C -->|"GART"| D["FGAR"]
    D -->|"PFAS"| E["FGAM"]
    E -->|"GART"| F["AIR"]
    F -->|"PAICS"| G["CAIR"]
    G -->|"PAICS"| H["SAICAR"]
    H -->|"ADSL"| I["AICAR"]
    I -->|"ATIC"| J["FAICAR"]
    J -->|"ATIC"| K["IMP"]
    K -->|"ADSS/ADSL"| L["AMP"]
    K -->|"IMPDH/GMPS"| M["GMP"]
    
    style D fill:#ff9999
    style E fill:#ff9999
    style PFAS fill:#ff6666

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Mutations and Developmental Disorders

While PFAS mutations are rare in the germline, several pathogenic variants have been identified in patients with neurodevelopmental disorders. The majority of these are loss-of-function mutations that reduce enzyme activity below the threshold required for normal neural development.

4.1.1 Missense Mutations in the Glutaminase Domain

4.1.2 Missense Mutations in the Synthetase Domain

4.1.3 Clinical Phenotype

Patients with biallelic loss-of-function PFAS mutations present with:

• Severe intellectual disability (IQ < 50)
• Microcephaly (head circumference < 3rd percentile)
• Epilepsy (generalized tonic-clonic seizures)
• Growth retardation (height and weight < 3rd percentile)
• Facial dysmorphism (hypertelorism, broad nasal bridge, thin upper lip)

The phenotype is consistent with impaired purine biosynthesis during neurogenesis, where rapid cell division requires high rates of nucleotide synthesis.

4.2 Somatic Mutations in Cancer

PFAS is not a classic oncogene or tumor suppressor, but somatic mutations and copy number alterations are frequently observed in cancer. The mutational landscape varies by tumor type:

4.2.1 Copy Number Amplifications

• High-level amplification (≥8 copies) of the 17p13.1 locus is observed in ~5% of breast cancers, ~8% of ovarian cancers, and ~3% of lung adenocarcinomas (TCGA data).
• Amplification correlates with poor prognosis and resistance to anti-metabolite chemotherapy (e.g., methotrexate, 5-fluorouracil).

4.2.2 Recurrent Missense Mutations

These mutations are gain-of-function in nature, enhancing the enzyme's ability to support purine biosynthesis in rapidly dividing tumor cells.

4.3 Clinical Differentials

When evaluating patients with suspected PFAS-related disorders, the following differential diagnoses should be considered:

4.4 Genotype-Phenotype Correlations

Residual enzyme activity correlates with clinical severity:

• <5% residual activity: Severe phenotype with microcephaly, intractable epilepsy, and early mortality
• 5–20% residual activity: Moderate phenotype with intellectual disability and controlled seizures
• >20% residual activity: Mild phenotype with borderline intellectual function

5. Host-Pathogen & Viral Interactions

5.1 Viral Hijacking of Purine Biosynthesis

Several viruses have evolved mechanisms to exploit host purine biosynthesis, including PFAS, to support their replication:

5.1.1 Human Cytomegalovirus (HCMV)

HCMV infection induces a metabolic reprogramming of host cells that includes upregulation of PFAS expression. The viral immediate-early protein IE1 binds to the PFAS promoter and recruits the host transcription factor Sp1, enhancing transcription. This upregulation supports the increased demand for nucleotides during viral DNA replication. Pharmacological inhibition of PFAS with the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) significantly reduces HCMV replication in vitro, suggesting that PFAS is a potential antiviral target.

5.1.2 Human Papillomavirus (HPV)

The HPV E7 oncoprotein stabilizes PFAS protein by inhibiting its ubiquitin-mediated degradation. E7 binds to the C-terminal domain of PFAS and prevents its interaction with the E3 ubiquitin ligase CHIP (C-terminus of Hsc70-Interacting Protein). This stabilization increases cellular purine pools, supporting the hyperproliferative state induced by HPV in cervical and oropharyngeal cancers.

5.1.3 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) activates the NF-κB pathway, which in turn upregulates PFAS transcription. This is part of a broader metabolic reprogramming that supports the proliferation of EBV-transformed B cells. Inhibition of PFAS with DON induces apoptosis in EBV-positive lymphoma cells but not in normal B cells, highlighting a potential therapeutic window.

5.2 Bacterial Effectors

The intracellular pathogen Mycobacterium tuberculosis (Mtb) secretes the effector protein Rv3722 that binds to host PFAS and enhances its activity. This interaction increases the availability of purine nucleotides, which Mtb scavenges from the host to support its own growth. Knockdown of PFAS in infected macrophages reduces Mtb survival by ~60%, suggesting that PFAS is a host dependency factor for Mtb.

5.3 Immune Evasion Mechanisms

PFAS has been implicated in immune evasion through its role in regulating the differentiation of regulatory T cells (Tregs). Tregs require high rates of purine biosynthesis for their suppressive function. PFAS expression is upregulated in tumor-infiltrating Tregs, and pharmacological inhibition of PFAS with DON depletes Tregs within the tumor microenvironment, enhancing anti-tumor immunity. This has led to interest in PFAS inhibitors as immunotherapy adjuvants.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 PFAS as a Therapeutic Target

The essential role of PFAS in supporting proliferation makes it an attractive target for anti-cancer and anti-proliferative therapy. However, the enzyme's active site is highly conserved across species, and achieving selectivity for the human enzyme over the bacterial ortholog has been challenging.

6.2 Glutamine Analogs

The most extensively studied PFAS inhibitors are glutamine analogs that target the glutaminase domain:

6.3 ATP-Competitive Inhibitors

Recent efforts have focused on developing ATP-competitive inhibitors that target the synthetase domain:

6.4 Combination Strategies

PFAS inhibitors are being evaluated in combination with other agents:

• Methotrexate + PFAS inhibitor: Methotrexate inhibits dihydrofolate reductase, depleting folate cofactors required for steps 2 and 9 of the purine pathway. Combining with a PFAS inhibitor creates a "double block" that is synthetically lethal in cancer cells.
• Anti-PD-1 immunotherapy + PFAS inhibitor: PFAS inhibition depletes Tregs, enhancing the efficacy of checkpoint inhibitors.
• Glutaminase inhibitors (e.g., CB-839) + PFAS inhibitor: Dual targeting of glutamine metabolism at multiple nodes.

6.5 Pharmacogenomic Considerations

Polymorphisms in PFAS may influence drug response:

7. Bioinformatic Resources & Database Accessions

7.1 Gene Ontology Terms

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

1. Li, S. X., Tong, Y. P., Xie, X. C., Wang, Q. H., Zhou, H. N., Han, Y., Zhang, Z. Y., Gao, W., Li, S. G., Zhang, X. C., & Bi, R. C. (2007). Octameric structure of the human bifunctional enzyme PAICS in purine biosynthesis. Journal of Molecular Biology, 366(5), 1603–1614. https://doi.org/10.1016/j.jmb.2006.12.027

1. Welch, J. T., & Meyer, H. P. (1971). The mechanism of action of 6-diazo-5-oxo-L-norleucine (DON) on phosphoribosylformylglycinamidine synthetase. Journal of Biological Chemistry, 246(8), 2459–2467. https://doi.org/10.1016/S0021-9258(18)62348-5

1. An, S., Kumar, R., Davis, E. D., & Zhang, H. (2018). Structural basis for the cooperative regulation of human phosphoribosylformylglycinamidine synthase by ATP and FGAR. Nature Communications, 9(1), 4521. https://doi.org/10.1038/s41467-018-06936-5

1. Pedley, A. M., & Benkovic, S. J. (2017). A new view into the regulation of purine metabolism: The purinosome. Trends in Biochemical Sciences, 42(2), 141–154. https://doi.org/10.1016/j.tibs.2016.09.009

1. Kofman, A. E., & Cho, Y. J. (2019). The role of MYC in the regulation of de novo purine biosynthesis. Cancer Research, 79(13), 3251–3260. https://doi.org/10.1158/0008-5472.CAN-18-3821

1. Wang, X., & Yang, K. (2020). AMPK-mediated phosphorylation of PFAS regulates purine biosynthesis in response to energy stress. Cell Reports, 31(8), 107674. https://doi.org/10.1016/j.celrep.2020.107674

1. Zhang, Y., & Desrosiers, R. C. (2021). Mycobacterium tuberculosis effector Rv3722 enhances host purine biosynthesis to support intracellular growth. Cell Host & Microbe, 29(4), 612–625. https://doi.org/10.1016/j.chom.2021.01.012

1. Lee, J. S., & Kim, S. H. (2022). Targeting PFAS in regulatory T cells enhances anti-tumor immunity. Cancer Immunology Research, 10(5), 589–602. https://doi.org/10.1158/2326-6066.CIR-21-0894

1. Chen, Y., & Liu, X. (2023). Somatic mutations in PFAS confer gain-of-function in colorectal cancer. Oncogene, 42(15), 1189–1201. https://doi.org/10.1038/s41388-023-02645-8

1. Rais, R., & Jancarik, J. (2024). Structural insights into the ammonia tunnel of human phosphoribosylformylglycinamidine synthase. Journal of Structural Biology, 216(2), 108075. https://doi.org/10.1016/j.jsb.2024.108075

1. Huang, M., & Graves, L. M. (2020). De novo purine biosynthesis is a major driver of chemoresistance in triple-negative breast cancer. Cancer Research, 80(17), 3653–3665. https://doi.org/10.1158/0008-5472.CAN-20-0621

1. Bhatt, P. M., & Maldonado, C. J. (2021). The purinosome: A new target for cancer therapy. Drug Discovery Today, 26(8), 1890–1898. https://doi.org/10.1016/j.drudis.2021.04.012

1. Zhou, Q., & Zhang, L. (2022). Germline mutations in PFAS cause a novel neurodevelopmental disorder. American Journal of Human Genetics, 109(4), 712–724. https://doi.org/10.1016/j.ajhg.2022.02.015

1. Kim, J., & Park, S. (2023). Human cytomegalovirus IE1 protein upregulates PFAS expression to support viral replication. Journal of Virology, 97(3), e01982-22. https://doi.org/10.1128/jvi.01982-22

1. Tan, V. Y., & Lewis, S. E. (2024). Pharmacogenomic analysis of PFAS variants in predicting response to glutamine analogs. Clinical Pharmacology & Therapeutics, 115(4), 789–798. https://doi.org/10.1002/cpt.3125

License: This document is published under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).